• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过动力学分析对拉西地平的钙拮抗作用进行定量。

Quantification of the calcium antagonism of lacidipine by kinetic analysis.

作者信息

Giacometti A, Micheli D, Gaviraghi G, Trist D G

机构信息

Glaxo Research Laboratories, Verona, Italy.

出版信息

J Pharmacol Exp Ther. 1994 Apr;269(1):424-9.

PMID:8169848
Abstract

The calcium antagonist activity of the long-acting 1,4-dihydropyridine (DHP) lacidipine has been analyzed in rabbit basilar artery using a washout design in constant depolarizing conditions. From the kinetics of the loss of effect with washing, it was possible to fit a model that included the rate constant for dissociation of the DHP from the membrane (k-1) together with its affinity for the voltage-activated channel (K2). The k-1 values for lacidipine and two other DHPs (amlodipine and nifedipine) have been calculated as 0.0098, 0.0182 and 0.166 min-1, respectively. Assuming that the externally applied concentration of the DHP reflected the concentration in the membrane, the apparent pK2 values of 9.80, 9.0 and 9.25 were calculated for the three calcium antagonists. These values are in good agreement with those estimated in a previous study. When the partition of lacidipine into the membrane was taken into consideration, its apparent pK2 was reduced to 4.85. Thus, the study reinforces the concept that the high membrane partition of lacidipine contributes not only to its duration of action but also to its very high potency.

摘要

长效1,4 - 二氢吡啶(DHP)拉西地平的钙拮抗剂活性已在兔基底动脉中采用恒流去极化条件下的洗脱设计进行了分析。根据洗脱时效应丧失的动力学,有可能拟合一个模型,该模型包括DHP从膜上解离的速率常数(k-1)及其对电压激活通道的亲和力(K2)。拉西地平和另外两种DHP(氨氯地平和硝苯地平)的k-1值分别计算为0.0098、0.0182和0.166 min-1。假设外部施加的DHP浓度反映了膜中的浓度,则计算出这三种钙拮抗剂的表观pK2值分别为9.80、9.0和9.25。这些值与先前研究中估计的值高度一致。当考虑拉西地平在膜中的分配时,其表观pK2降至4.85。因此,该研究强化了这样一个概念,即拉西地平的高膜分配不仅有助于其作用持续时间,也有助于其非常高的效力。

相似文献

1
Quantification of the calcium antagonism of lacidipine by kinetic analysis.通过动力学分析对拉西地平的钙拮抗作用进行定量。
J Pharmacol Exp Ther. 1994 Apr;269(1):424-9.
2
Analysis of the interaction between lacidipine and BAY K 8644 in two isolated rabbit arteries.拉西地平与BAY K 8644在两条离体兔动脉中的相互作用分析。
J Pharmacol Exp Ther. 1992 Dec;263(3):1241-7.
3
Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.新型1,4 - 二氢吡啶类钙拮抗剂乐卡地平的体外药理学研究
Arzneimittelforschung. 1996 Jan;46(1):15-24.
4
Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.1,4 - 二氢吡啶类药物伊拉地平与拉西地平与平滑肌钙通道相互作用的放射性配体及功能评估
Br J Pharmacol. 1993 May;109(1):100-6. doi: 10.1111/j.1476-5381.1993.tb13537.x.
5
Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.乐卡地平:血浆半衰期短、作用持续时间长且胆固醇耐受性高。更新分子模型以阐明其药代动力学特性。
Blood Press Suppl. 1998;2:10-7.
6
Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.胆固醇会改变钙离子通道阻滞剂与膜脂双层的结合。
Mol Pharmacol. 1992 Feb;41(2):315-21.
7
Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.二氢吡啶类钙拮抗剂的药理学:亲脂性与药效学反应之间的关系。
J Hypertens Suppl. 1993 Dec;11(6):S3-8.
8
Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.重组高亲和力二氢吡啶结合域的保守钙离子拮抗剂结合特性及推测的折叠结构
Biochem J. 2000 May 1;347 Pt 3(Pt 3):829-36.
9
Different antioxidative potencies of dihydropyridine calcium channel modulators in various models.二氢吡啶类钙通道调节剂在不同模型中的不同抗氧化能力。
Vascul Pharmacol. 2005 Mar;42(4):145-52. doi: 10.1016/j.vph.2004.11.003. Epub 2005 Jan 22.
10
Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.Bay K8644对钙通道拮抗剂抑制L型钙通道电流的竞争性和协同作用。
J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. doi: 10.1124/jpet.107.122176. Epub 2007 May 2.

引用本文的文献

1
Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.拉西地平。对其药效学、药代动力学特性及治疗高血压的潜力的综述。
Drugs. 1994 Aug;48(2):274-96. doi: 10.2165/00003495-199448020-00010.